A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
ALX Oncology Inc.
BicycleTx Limited
NiKang Therapeutics, Inc.
Pfizer
Pliant Therapeutics, Inc.
Eli Lilly and Company
AstraZeneca
MOMA Therapeutics
Eli Lilly and Company
Kivu Bioscience Inc.
MOMA Therapeutics
Astellas Pharma Inc
Edwards Lifesciences
Eli Lilly and Company
7 Hills Pharma, LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Plexium, Inc.
Beijing Biotech
Parabilis Medicines, Inc.
Revolution Medicines, Inc.
Pfizer
USWM, LLC (dba US WorldMeds)
Coherus Oncology, Inc.
Lumos Pharma
Actuate Therapeutics Inc.
Conjupro Biotherapeutics, Inc.
Taiho Oncology, Inc.
Alterome Therapeutics, Inc.
IDEAYA Biosciences
Aulos Bioscience, Inc.
Buzzard Pharmaceuticals
iOnctura
Boston Scientific Corporation
Aptamer Sciences, Inc.
Erasca, Inc.
Novartis
GlaxoSmithKline
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Orano Med LLC
Artios Pharma Ltd
Novartis
Frontier Medicines Corporation
Beijing Biotech
PMV Pharmaceuticals, Inc
Imugene Limited
I-Mab Biopharma US Limited
ViroMissile, Inc.
Engeneic Pty Limited